Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

  • Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

    SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

  • Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NGjFNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX4U45KSzVyPUCuNFAxOzB|IN88US=> NGDSNHdUSU6JRWK=
IST-MEL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMECwOFA4KM7:TR?= NFjkUmZUSU6JRWK=
NCI-SNU-1 NFX4UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCyTWM2OD1yLkCwNlA4KM7:TR?= MlrDV2FPT0WU
FADU MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS5dHJKSzVyPUCuNFAzODlizszN NFTsWW1USU6JRWK=
C32 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLSTWM2OD1yLkCwN|A1KM7:TR?= M2fyXXNCVkeHUh?=
D-566MG MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13nUGlEPTB;MD6wNFM6KM7:TR?= NHPiTnpUSU6JRWK=
LXF-289 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q5cWlEPTB;MD6wNFQyQSEQvF2= MXLTRW5ITVJ?
HGC-27 M3nWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\zNlZiUUN3ME2wMlAxPTFizszN MXfTRW5ITVJ?
RPMI-7951 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXpPZBFUUN3ME2wMlAxPzF5IN88US=> NX;Qe45yW0GQR1XS
HSC-3 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm3[3hKSzVyPUCuNFA6OjlizszN MVvTRW5ITVJ?
MIA-PaCa-2 NFzqXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjnS|NiUUN3ME2wMlAyODB7IN88US=> MVjTRW5ITVJ?
KS-1 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1yLkCxN|U2KM7:TR?= NXSwWnJEW0GQR1XS
CAL-51 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPXSGdKSzVyPUCuNFE1ODVizszN MU\TRW5ITVJ?
MDA-MB-361 NEm4W5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHmZWRSUUN3ME2wMlAyPDl3IN88US=> NV;HUY5zW0GQR1XS
TI-73 M1W4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7sZ5NKSzVyPUCuNFE4QTZizszN M4DyenNCVkeHUh?=
AGS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[2TWM2OD1yLkCxPVM5KM7:TR?= NVHpfmtmW0GQR1XS
NCI-H460 NFSx[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEG5O|Qh|ryP Mn;RV2FPT0WU
A204 NVHsXWVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzBTWM2OD1yLkCyNlQ6KM7:TR?= MV7TRW5ITVJ?
CHL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEKyOVEh|ryP MWXTRW5ITVJ?
DU-4475 M1ntTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XiOGlEPTB;MD6wNlI3OSEQvF2= MXvTRW5ITVJ?
CGTH-W-1 M1n0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvoZWl{UUN3ME2wMlAzOzR7IN88US=> Ml;JV2FPT0WU
HCC2218 NX;LdJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfCNIJKSzVyPUCuNFI1QTRizszN M2fFPXNCVkeHUh?=
A2780 M1HmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3cWlEPTB;MD6wNlU{OSEQvF2= MnKyV2FPT0WU
NCI-H720 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1yLkCyOVQ3KM7:TR?= MnzMV2FPT0WU
NCI-N87 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEK1PVMh|ryP M3rFR3NCVkeHUh?=
CHP-212 M4ThNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ntXGlEPTB;MD6wNlYzQCEQvF2= M2G0d3NCVkeHUh?=
NCI-H23 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTyTWM2OD1yLkCyOlY2KM7:TR?= NXT5VGo3W0GQR1XS
D-263MG M331bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrZTWM2OD1yLkCyO|g3KM7:TR?= M1K2[HNCVkeHUh?=
ME-180 NGjHe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m4eGlEPTB;MD6wNlg6OSEQvF2= NH;GTGJUSU6JRWK=
SW982 M33HW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzWoNnUUN3ME2wMlAzQTl7IN88US=> NGKybVlUSU6JRWK=
OE19 NGSwXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GzPWlEPTB;MD6wN|A4PyEQvF2= MUjTRW5ITVJ?
SK-LU-1 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDvd5NZUUN3ME2wMlA{ODh{IN88US=> MknRV2FPT0WU
H4 NXrqbo5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEOwPUDPxE1? Mm\ZV2FPT0WU
HT-144 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X0RWlEPTB;MD6wN|A6OyEQvF2= M3HMOHNCVkeHUh?=
SK-UT-1 NU\ZNXpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWeyN2ZZUUN3ME2wMlA{OTd6IN88US=> NWnuOHFZW0GQR1XS
D-336MG NHvsW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W4VWlEPTB;MD6wN|MxQSEQvF2= MW\TRW5ITVJ?
MDA-MB-175-VII NVy0VXk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhWWRQUUN3ME2wMlA{OzV2IN88US=> MUDTRW5ITVJ?
GAMG Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXiwNm8xUUN3ME2wMlA{PDN3IN88US=> M{fQTnNCVkeHUh?=
CP50-MEL-B M3X6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtTWM2OD1yLkCzOFUh|ryP M2\kc3NCVkeHUh?=
OVCAR-5 NV;Cd2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vGWGlEPTB;MD6wN|Q5KM7:TR?= MYPTRW5ITVJ?
SK-MES-1 M1;LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHUTWM2OD1yLkCzOlA3KM7:TR?= M1LJXnNCVkeHUh?=
VM-CUB-1 NGKxUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHCTVJUUUN3ME2wMlA{PjV5IN88US=> M{fidnNCVkeHUh?=
WM-115 NF3ndFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljQTWM2OD1yLkCzO|YzKM7:TR?= NV3GUI54W0GQR1XS
DSH1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrWeYNmUUN3ME2wMlA{QDB5IN88US=> MmTCV2FPT0WU
Becker MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEO4PFUh|ryP MWXTRW5ITVJ?
SW962 M{H5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTGTWM2OD1yLkCzPVQ2KM7:TR?= M{SwZ3NCVkeHUh?=
TYK-nu NFfESYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;wTWM2OD1yLkCzPVg2KM7:TR?= M{[0c3NCVkeHUh?=
HO-1-N-1 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\KTWM2OD1yLkC0NFIyKM7:TR?= M1;oWnNCVkeHUh?=
T98G NXH6S|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnTWFlKSzVyPUCuNFQyODNizszN NVSzUGZDW0GQR1XS
ACN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPMTWM2OD1yLkC0NVYzKM7:TR?= MljXV2FPT0WU
SW780 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF64T|BKSzVyPUCuNFQzODNizszN M1O0bXNCVkeHUh?=
Detroit562 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmyXohoUUN3ME2wMlA1OjN7IN88US=> M1zMUnNCVkeHUh?=
BB49-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Kd254UUN3ME2wMlA1OjR|IN88US=> MV;TRW5ITVJ?
HN NFHMcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLyTWM2OD1yLkC0NlczKM7:TR?= MkXNV2FPT0WU
H9 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETHXIhKSzVyPUCuNFQ{PzFizszN NGD3ZZNUSU6JRWK=
VA-ES-BJ M13ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETGeFlKSzVyPUCuNFQ1PDdizszN MX\TRW5ITVJ?
MEL-JUSO NXrzeWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[5V|h7UUN3ME2wMlA1PDd3IN88US=> MX7TRW5ITVJ?
BT-474 NXPa[YVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMES1JO69VQ>? NXHiRm9uW0GQR1XS
CaR-1 M3fmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL5PHMyUUN3ME2wMlA1PTR7IN88US=> M1PFS3NCVkeHUh?=
PSN1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzMSYpKSzVyPUCuNFQ3ODNizszN NH;sNHpUSU6JRWK=
KYSE-510 NXS4[5BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMES2OFkh|ryP NVfXO2xoW0GQR1XS
KP-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMES3OVMh|ryP NUDyXIRIW0GQR1XS
KYSE-410 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMES3O|Ih|ryP MWDTRW5ITVJ?
G-402 NUnzflBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7i[IdEUUN3ME2wMlA1Pzh7IN88US=> M{LQN3NCVkeHUh?=
DOK MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLaVXZGUUN3ME2wMlA1QTB{IN88US=> NViz[3lPW0GQR1XS
COR-L88 NXjsS|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PxZmlEPTB;MD6wOFkyOiEQvF2= M2exT3NCVkeHUh?=
SKG-IIIa NY\5W3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXbVlKSzVyPUCuNFQ6QDZizszN MnTlV2FPT0WU
AN3-CA M2roNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiyS4FKSzVyPUCuNFUh|ryP MmTYV2FPT0WU
SW48 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMEWwN|kh|ryP NUD4b4REW0GQR1XS
YKG-1 NF[3b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhcmlEPTB;MD6wOVA4OSEQvF2= NVzkSmx6W0GQR1XS
KYSE-150 M2Hp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnufHlQUUN3ME2wMlA2OjN3IN88US=> MXPTRW5ITVJ?
HuO-3N1 M3rSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf0NFhoUUN3ME2wMlA2OjN5IN88US=> NXHNUZhNW0GQR1XS
LB1047-RCC M4\ZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7QTWM2OD1yLkC1Nlk3KM7:TR?= NILWcZdUSU6JRWK=
NCI-H2030 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEW0NVQh|ryP NGWwbYJUSU6JRWK=
YH-13 M1Ps[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhZoZ1UUN3ME2wMlA2PzJ{IN88US=> MlzNV2FPT0WU
5637 NH;DXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TRfGlEPTB;MD6wOVc1KM7:TR?= MoPxV2FPT0WU
LOXIMVI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\kUWhKSzVyPUCuNFU5PzJizszN MWLTRW5ITVJ?
GT3TKB NH7oXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3mTWM2OD1yLkC1PVQzKM7:TR?= MXzTRW5ITVJ?
TCCSUP M3vue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT3codtUUN3ME2wMlA2QTZ2IN88US=> MkG5V2FPT0WU
EPLC-272H MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwME[yNFUh|ryP MY\TRW5ITVJ?
LU-99A NXfle3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwME[yN|ch|ryP MkHxV2FPT0WU
NCI-H1755 NXHtcph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHybFZKSzVyPUCuNFY{PDFizszN Ml\0V2FPT0WU
KM12 M133b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjs[mRKSzVyPUCuNFY{PDhizszN NXLMelFvW0GQR1XS
SF295 NFHWeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHCZlZKSzVyPUCuNFY1PTJizszN NWTKWpU4W0GQR1XS
MZ2-MEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPvTWM2OD1yLkC2OVU{KM7:TR?= Mo\GV2FPT0WU
HEC-1 NWTmOXhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZXlhKSzVyPUCuNFY2QDhizszN NIj6Z|VUSU6JRWK=
SW684 NUXW[4N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jLfWlEPTB;MD6wOlU6OSEQvF2= M1jSOnNCVkeHUh?=
SF539 NXTGbpRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTVUmpKSzVyPUCuNFY3QDFizszN Mm\3V2FPT0WU
GMS-10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LT[WlEPTB;MD6wOlY6QSEQvF2= M4nlOXNCVkeHUh?=
MV-4-11 NV3scWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrWo9rUUN3ME2wMlA3QDB|IN88US=> M2LGd3NCVkeHUh?=
HT-29 NIfFXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwME[5NVkh|ryP MYHTRW5ITVJ?
23132-87 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rmdmlEPTB;MD6wOlk2KM7:TR?= NEDodZVUSU6JRWK=
SW620 M3PuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDETlEzUUN3ME2wMlA4ODJ4IN88US=> M3P0c3NCVkeHUh?=
HCC1806 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTxTWM2OD1yLkC3NVMyKM7:TR?= NYO0PI9PW0GQR1XS
Hs-578-T NVLyRZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXkTWM2OD1yLkC3NlA5KM7:TR?= M2XSNnNCVkeHUh?=
A2058 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\z[4h4UUN3ME2wMlA4OjJ6IN88US=> M2GyN3NCVkeHUh?=
MEL-HO NVTpU2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1OpBKSzVyPUCuNFczPTVizszN MUXTRW5ITVJ?
HCC2998 NVXFVJg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEezOFch|ryP MWHTRW5ITVJ?
HuO9 M2rXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDSc251UUN3ME2wMlA4PTh7IN88US=> MnLzV2FPT0WU
CAL-39 M2nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjLTWM2OD1yLkC3O|Y3KM7:TR?= MVPTRW5ITVJ?
M14 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxcmlEPTB;MD6wO|kyOyEQvF2= MnniV2FPT0WU
BFTC-909 NYW2O2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P5V2lEPTB;MD6wO|k3QSEQvF2= NF7U[4lUSU6JRWK=
TE-11 MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD1yLkC3PVk3KM7:TR?= M3HZe3NCVkeHUh?=
TGBC1TKB M4\MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\pTWM2OD1yLkC4NFQ{KM7:TR?= NEjzc4lUSU6JRWK=
L-363 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvXWWhyUUN3ME2wMlA5OjB4IN88US=> M3\0bHNCVkeHUh?=
A431 NYW4R2NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD1yLkC4NlEh|ryP M4j3PXNCVkeHUh?=
MKN45 NVm2UHVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;sdoZZUUN3ME2wMlA5OjF7IN88US=> MofJV2FPT0WU
HT-1080 M3;JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzSTWM2OD1yLkC4OFM6KM7:TR?= NETPOGVUSU6JRWK=
OVCAR-8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD1yLkC4OlIzKM7:TR?= Ml2yV2FPT0WU
LCLC-97TM1 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HSd2lEPTB;MD6wPFczQCEQvF2= NYOxcFk5W0GQR1XS
M059J MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEmwNlch|ryP MYfTRW5ITVJ?
SK-MEL-2 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEmwOkDPxE1? M2e4V3NCVkeHUh?=
TE-1 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxbmlKSzVyPUCuNFkzODRizszN MnPrV2FPT0WU
KYSE-180 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX3TWM2OD1yLkC5NlYzKM7:TR?= M3q1dnNCVkeHUh?=
D-247MG M2Lmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEm0OVUh|ryP NUe1XHJ7W0GQR1XS
8-MG-BA NHW0S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[yZlZKSzVyPUCuNFk1PzJizszN M1HSd3NCVkeHUh?=
NCI-H1792 NH:0XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEm2NVgh|ryP MVnTRW5ITVJ?
MCF7 M{KzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPHTWM2OD1yLkC5Olc4KM7:TR?= NVTLSIxbW0GQR1XS
NCI-H2122 M{PuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEm3OFUh|ryP M1XGeHNCVkeHUh?=
EFO-27 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEm5PVch|ryP NUDUXZk1W0GQR1XS
LB2241-RCC NIHtb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4NWlEPTB;MD6xNFA2PCEQvF2= NVr0ZpZRW0GQR1XS
SN12C NIfBSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Th[2lEPTB;MD6xNFExPyEQvF2= M4jNSnNCVkeHUh?=
A498 NWK1[YtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne0TWM2OD1yLkGwNVgh|ryP NGS4RZZUSU6JRWK=
PANC-03-27 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUCyPFYh|ryP M4P4TnNCVkeHUh?=
NCI-H1581 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;CR5VKSzVyPUCuNVAzQSEQvF2= Mlj5V2FPT0WU
U-87-MG M4XUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jnT2lEPTB;MD6xNFMxPyEQvF2= MUjTRW5ITVJ?
G-401 M3PJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1yLkGwN|U{KM7:TR?= NXPGSoNYW0GQR1XS
SiHa NVGzO5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS2TWM2OD1yLkGwOFg3KM7:TR?= M2HiVHNCVkeHUh?=
U251 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHYOW9KSzVyPUCuNVA2OjVizszN M1naOXNCVkeHUh?=
MMAC-SF NY[zNoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUC1N|Eh|ryP NYPjfIh7W0GQR1XS
BB65-RCC NELaWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfNcGFKSzVyPUCuNVA2PTRizszN M4jYeXNCVkeHUh?=
NKM-1 NEL2[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PlS2lEPTB;MD6xNFY3PiEQvF2= M2TPcnNCVkeHUh?=
HD-MY-Z M{H5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfjZ2I3UUN3ME2wMlExQDd|IN88US=> NVHDSoN{W0GQR1XS
TGBC11TKB M3PFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUC5NFMh|ryP NV[zWpVVW0GQR1XS
COLO-679 NHHuOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwe2ZHUUN3ME2wMlEyOjFzIN88US=> MXTTRW5ITVJ?
TE-8 NXu0dGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HkXGlEPTB;MD6xNVI3PCEQvF2= MUXTRW5ITVJ?
SK-MEL-28 NV7vfoI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHLTWM2OD1yLkGxN|IyKM7:TR?= NIDDZYtUSU6JRWK=
SH-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqxcYJKSzVyPUCuNVE{PTZizszN NYm5NJB5W0GQR1XS
KALS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPCeZlKSzVyPUCuNVE{QTNizszN MmD4V2FPT0WU
RKO NWHYTGtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUG3OlQh|ryP MnnOV2FPT0WU
OMC-1 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Lu[2lEPTB;MD6xNVc6PyEQvF2= M17VVXNCVkeHUh?=
BT-549 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHz[|huUUN3ME2wMlEyPzl7IN88US=> NHW2[oZUSU6JRWK=
NCI-H28 NIO2OoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\C[HdKSzVyPUCuNVE5OTdizszN MYnTRW5ITVJ?
RXF393 M3:3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMUG5PFIh|ryP M1y4ZXNCVkeHUh?=
COLO-829 NFvWZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMUKwNFUh|ryP MYPTRW5ITVJ?
HMV-II M13hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnMc3ZlUUN3ME2wMlEzODJizszN MnWyV2FPT0WU
SW1990 M{nz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqxfYZKSzVyPUCuNVIyPTdizszN NGDjc4FUSU6JRWK=
NCI-H1437 M1qxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD1yLkGyNVU4KM7:TR?= MYDTRW5ITVJ?
SNB75 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\XTWM2OD1yLkGyNVY6KM7:TR?= NETEUZZUSU6JRWK=
EW-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUK2OlEh|ryP M{fCPXNCVkeHUh?=
SAS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HTO2lEPTB;MD6xNlY6KM7:TR?= MVXTRW5ITVJ?
NCI-H1666 NXjUZXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;4TWM2OD1yLkGyO|c1KM7:TR?= MY\TRW5ITVJ?
A375 NYTo[2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUK3O|gh|ryP NVn6VHM2W0GQR1XS
CAMA-1 M1i4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDDd|dyUUN3ME2wMlEzQTJ2IN88US=> NVLuRnhsW0GQR1XS
HuP-T4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMUK5OFMh|ryP NH3EW2tUSU6JRWK=
NCI-H292 NIO0XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nQ[2lEPTB;MD6xN|EyKM7:TR?= MoX4V2FPT0WU
PC-14 M4HhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD1yLkGzNlEyKM7:TR?= M{L3c3NCVkeHUh?=
BPH-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7WTWM2OD1yLkGzOFEh|ryP Ml;DV2FPT0WU
GAK M1T0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjwUHZJUUN3ME2wMlE{PTZ5IN88US=> NHfhU|RUSU6JRWK=
VMRC-RCZ Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrNdIVpUUN3ME2wMlE{PzZ{IN88US=> MWHTRW5ITVJ?
SK-MEL-24 NHfPfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX6XXFGUUN3ME2wMlE{QDdizszN NFO1Z25USU6JRWK=
LB831-BLC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf6dJFTUUN3ME2wMlE{QDh|IN88US=> NUjtWHNkW0GQR1XS
NCI-H2452 M4TjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTFOZFKSzVyPUCuNVM6PTZizszN NHrHUGNUSU6JRWK=
RT-112 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPbVJKSzVyPUCuNVQxOzVizszN M3rrVnNCVkeHUh?=
GP5d Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ne5pKSzVyPUCuNVQyODRizszN NYn5dXRnW0GQR1XS
LC-2-ad NFHHUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUSxNlEh|ryP MYjTRW5ITVJ?
MPP-89 M1jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDnTWM2OD1yLkG0NVI2KM7:TR?= MXfTRW5ITVJ?
NUGC-3 NHz0ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zsNWlEPTB;MD6xOFQ4QCEQvF2= Mmq5V2FPT0WU
GI-1 NYO4eXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ve3pNUUN3ME2wMlE1PTV6IN88US=> M2rsU3NCVkeHUh?=
HCC1419 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[0TWM2OD1yLkG0OVc3KM7:TR?= M176SnNCVkeHUh?=
SW1573 M4LqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzF[3F4UUN3ME2wMlE1PzV6IN88US=> NYWwd2J7W0GQR1XS
NCI-H2347 NX7lZXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUS4N|kh|ryP MoLlV2FPT0WU
Mewo NWryVnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HpVWlEPTB;MD6xOFg5QSEQvF2= M3fWeHNCVkeHUh?=
639-V NWjhSpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1yLkG1NFE{KM7:TR?= M{f3V3NCVkeHUh?=
AsPC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\vUGVDUUN3ME2wMlE2OjJ3IN88US=> NXy2OVhHW0GQR1XS
NCI-H1648 M2jWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm0OVFXUUN3ME2wMlE2OjN{IN88US=> MUHTRW5ITVJ?
786-0 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\zSWNsUUN3ME2wMlE2OzhzIN88US=> MX7TRW5ITVJ?
ETK-1 M13T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2yPGhUUUN3ME2wMlE2QSEQvF2= MYrTRW5ITVJ?
BxPC-3 NWXZcHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzSTWM2OD1yLkG1PVY3KM7:TR?= MXfTRW5ITVJ?
CAL-62 NV[3dlF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXjTWM2OD1yLkG2NVY6KM7:TR?= NH3hZo1USU6JRWK=
HCC1937 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHGbXk{UUN3ME2wMlE3Ojd3IN88US=> NXy1[YVjW0GQR1XS
NCI-H1299 M33xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjySFhYUUN3ME2wMlE3Ojh3IN88US=> M2C3VnNCVkeHUh?=
SW1088 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhN5hKSzVyPUCuNVY1OTNizszN Mmn4V2FPT0WU
FTC-133 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jve2lEPTB;MD6xOlU1KM7:TR?= NXm4NXhQW0GQR1XS
OC-314 NFjnXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fScmlEPTB;MD6xOlY6KM7:TR?= M4DveHNCVkeHUh?=
SCC-9 NXTuVGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[xTWM2OD1yLkG2O|E3KM7:TR?= M3zxb3NCVkeHUh?=
HT-1376 M3PSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGyTWM2OD1yLkG2PVM3KM7:TR?= MljwV2FPT0WU
U-2-OS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLsWIJLUUN3ME2wMlE4OTd|IN88US=> M3fEPXNCVkeHUh?=
COLO-824 NXTve457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD1yLkG3Nlk1KM7:TR?= MlnyV2FPT0WU
BB30-HNC M3XpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT3VnZzUUN3ME2wMlE4OzNizszN M161eXNCVkeHUh?=
NCI-H2087 NWrFcot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zx[mlEPTB;MD6xO|M3QCEQvF2= Mmi2V2FPT0WU
NCI-H2170 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsWnJKSzVyPUCuNVc2OzZizszN NGW2WZNUSU6JRWK=
SK-OV-3 NYL3bI1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMUe1O|Eh|ryP NH7xemdUSU6JRWK=
MZ7-mel MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTYTWM2OD1yLkG3OlQ6KM7:TR?= NIWwfWZUSU6JRWK=
NCI-H650 M4Xj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMUe2PFIh|ryP M3vmdnNCVkeHUh?=
KOSC-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TqWmlEPTB;MD6xO|c{PCEQvF2= NYjMSmV1W0GQR1XS
SCC-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPt[lZKSzVyPUCuNVc4PzdizszN M4S0OnNCVkeHUh?=
MDA-MB-157 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYZ2RKSzVyPUCuNVgxQDJizszN NF\SUI9USU6JRWK=
KYSE-520 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fG[mlEPTB;MD6xPFIh|ryP MnvpV2FPT0WU
LK-2 NECyeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP6TWM2OD1yLkG4N|A{KM7:TR?= NETTVIFUSU6JRWK=
KNS-81-FD MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35O4QxUUN3ME2wMlE5Ozl2IN88US=> NUixWYtNW0GQR1XS
IGROV-1 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TpSmlEPTB;MD6xPFQ1OyEQvF2= MlzYV2FPT0WU
DEL NFzMcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3[WJKSzVyPUCuNVg1PSEQvF2= NX3BfnZ2W0GQR1XS
NCI-H1395 NVX0fGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLNVZRxUUN3ME2wMlE5Pjh{IN88US=> MWLTRW5ITVJ?
JEG-3 NXLPRlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Sx[mlEPTB;MD6xPFcxPSEQvF2= NV;vXmlzW0GQR1XS
BCPAP NVL0OG9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rYU2lEPTB;MD6xPFg4OiEQvF2= MnvzV2FPT0WU
CAL-27 NVnEW4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn4TWM2OD1yLkG5NFIzKM7:TR?= M1jwcnNCVkeHUh?=
RD MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP3UYRKSzVyPUCuNVkyOTNizszN M4TZRnNCVkeHUh?=
RVH-421 NXvGdVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUmxNVYh|ryP NXfCUFVNW0GQR1XS
Capan-2 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\YTWM2OD1yLkG5NlU3KM7:TR?= MWPTRW5ITVJ?
COLO-680N M4PZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r4W2lEPTB;MD6xPVM3PCEQvF2= NFziR|hUSU6JRWK=
NCI-H1650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5NVdKSzVyPUCuNlAxPTdizszN MkS2V2FPT0WU
SBC-5 M{n3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DmdmlEPTB;MD6yNFEyQCEQvF2= MXrTRW5ITVJ?
U031 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PadmlEPTB;MD6yNFU1PyEQvF2= NY\HWItxW0GQR1XS
S-117 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOz[XNKSzVyPUCuNlA2PjRizszN NX7vW4l[W0GQR1XS
DoTc2-4510 NHXwWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH6cY1KSzVyPUCuNlA4PjlizszN NEnlW3dUSU6JRWK=
AM-38 M1K5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrSIJoUUN3ME2wMlIxQDR6IN88US=> MVLTRW5ITVJ?
A172 NIrFUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHPTWM2OD1yLkKxNFIzKM7:TR?= NUDubY9LW0GQR1XS
HPAF-II MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\qTWM2OD1yLkKxNlY1KM7:TR?= M3HvWXNCVkeHUh?=
769-P MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PiO2lEPTB;MD6yNVI5KM7:TR?= NYO0[5hkW0GQR1XS
MFE-280 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\JfnQyUUN3ME2wMlIyOjl6IN88US=> MV\TRW5ITVJ?
TE-9 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGxTWM2OD1yLkKxO|g3KM7:TR?= MWjTRW5ITVJ?
C2BBe1 M2nQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqzTWM2OD1yLkKyNVkh|ryP M4\hN3NCVkeHUh?=
EoL-1-cell M3LvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLhfoNKSzVyPUCuNlIzODNizszN NVPrdG9LW0GQR1XS
G-361 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTPTWM2OD1yLkKyOlgzKM7:TR?= Mmf0V2FPT0WU
KYSE-270 NX7uXpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnXTWM2OD1yLkKzNFg1KM7:TR?= MlnMV2FPT0WU
TK10 M3LDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37FZWlEPTB;MD6yN|EyPyEQvF2= NUPaSWZNW0GQR1XS
ML-2 M2rZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkOxNVkh|ryP NGnXUZVUSU6JRWK=
MHH-ES-1 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP0TWM2OD1yLkKzOlgyKM7:TR?= MnP6V2FPT0WU
BHY NFnKfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxWWlEPTB;MD6yN|Y6OSEQvF2= NYjiN3duW0GQR1XS
LS-513 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnUXGRKSzVyPUCuNlM6PjFizszN MYHTRW5ITVJ?
COLO-678 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD3fXpKSzVyPUCuNlQxPDRizszN NET2fGxUSU6JRWK=
NCI-H747 NW\HboI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvxXpMzUUN3ME2wMlI1OTZ7IN88US=> M1\WRXNCVkeHUh?=
K5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMkSzPEDPxE1? Ml;LV2FPT0WU
OS-RC-2 M3noNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMkS1NFkh|ryP NYHKS|V6W0GQR1XS
KINGS-1 NUT2Xm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMkS1Nlkh|ryP NVrPfmdUW0GQR1XS
SCC-25 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPtcXVwUUN3ME2wMlI1PTZ|IN88US=> NXLoUpU2W0GQR1XS
CAPAN-1 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXBZ3VKSzVyPUCuNlQ4QDNizszN MXvTRW5ITVJ?
ESS-1 M2CyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LjdmlEPTB;MD6yOFgxPSEQvF2= M2fGZnNCVkeHUh?=
TE-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3RmlnUUN3ME2wMlI2PzVizszN MVjTRW5ITVJ?
LB2518-MEL NWnQZY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XJdmlEPTB;MD6yOVc4PyEQvF2= NVLIfI1IW0GQR1XS
COLO-800 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnObmxKSzVyPUCuNlU5OTJizszN M33ZdnNCVkeHUh?=
LU-134-A M4fTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMk[xN|Yh|ryP M2PucXNCVkeHUh?=
NCI-H1155 NFLtWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKwTpRKSzVyPUCuNlYyPjJizszN NVW4XYVsW0GQR1XS
MFM-223 M{PqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WwXmlEPTB;MD6yOlM3OyEQvF2= NIPjPWdUSU6JRWK=
HTC-C3 NWXL[2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHt[HlKSzVyPUCuNlY2ODZizszN MVzTRW5ITVJ?
HCT-116 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjuWFcyUUN3ME2wMlI3PTl7IN88US=> NWTNVplkW0GQR1XS
Ca-Ski NEjxcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXrclg3UUN3ME2wMlI3Pjd6IN88US=> M{SzUnNCVkeHUh?=
SBC-1 NE[wPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2W2lEPTB;MD6yOlc1OiEQvF2= NF:wWXBUSU6JRWK=
NB69 M{D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD1yLkK3NFg4KM7:TR?= M3i0RXNCVkeHUh?=
J82 NWKzRmtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMkeyOlUh|ryP M17QeXNCVkeHUh?=
U-118-MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMke1O|kh|ryP MXzTRW5ITVJ?
NCI-H1355 NWK1XVduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMkiwO|Qh|ryP MYXTRW5ITVJ?
NCI-H1048 NWr6e2NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rod2lEPTB;MD6yPFk2PiEQvF2= M4TVdHNCVkeHUh?=
SW954 M3fpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ru[GlEPTB;MD6yPVIzPyEQvF2= Mn3UV2FPT0WU
NMC-G1 NF7IfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMkmyO|ch|ryP MX7TRW5ITVJ?
SW1710 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC5blJKSzVyPUCuNlk1QTRizszN NWX2VIU6W0GQR1XS
KY821 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMkm4O|Ih|ryP NFfv[oxUSU6JRWK=
HCC38 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnvUVFKSzVyPUCuN|AxPzhizszN Moi1V2FPT0WU
NCI-SNU-5 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLXWVlLUUN3ME2wMlMxPTRizszN NIHG[FlUSU6JRWK=
ES8 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3wW29KSzVyPUCuN|A4QDRizszN NXX0cmZ{W0GQR1XS
COLO-792 NXX2bHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NW2lEPTB;MD6zNVI2OSEQvF2= NHLNNmhUSU6JRWK=
BFTC-905 NYDpZopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwM{G1NlEh|ryP M3vkTnNCVkeHUh?=
ChaGo-K-1 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjJR4NKSzVyPUCuN|E4OTVizszN MnP6V2FPT0WU
Daoy NHnzNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwM{G3NlMh|ryP NHnpTIxUSU6JRWK=
SJSA-1 M{S3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rScmlEPTB;MD6zNVg1PyEQvF2= MmjDV2FPT0WU
KNS-62 NG\3XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ryXGlEPTB;MD6zNlA5QCEQvF2= M33sSHNCVkeHUh?=
CAKI-1 M2nkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\l[m1KSzVyPUCuN|IyOTFizszN NX7Z[odrW0GQR1XS
UACC-62 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFflNHZKSzVyPUCuN|IzOjdizszN M2PDTXNCVkeHUh?=
HuCCT1 NEjS[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jmN2lEPTB;MD6zNlI5OyEQvF2= MofEV2FPT0WU
CTB-1 NH71S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f1ZWlEPTB;MD6zNlc2OyEQvF2= MXTTRW5ITVJ?
NTERA-S-cl-D1 NXrIfZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpXGlEPTB;MD6zNlg{PiEQvF2= MlnjV2FPT0WU
T-24 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwM{OxOVkh|ryP M16w[XNCVkeHUh?=
KYSE-70 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DcJpKSzVyPUCuN|MzQDNizszN Mkm5V2FPT0WU
SW626 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rWOGlEPTB;MD6zN|U{OiEQvF2= MVTTRW5ITVJ?
LB996-RCC MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP1PHl2UUN3ME2wMlM{PjF7IN88US=> M3exZXNCVkeHUh?=
DMS-273 NXrQTWVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Lue2lEPTB;MD6zN|kyPiEQvF2= NYnlZ2lOW0GQR1XS
SW1783 NWPYNIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKzUIZKSzVyPUCuN|M6QTdizszN MVrTRW5ITVJ?
KU812 NV7uT3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW3XJVKSzVyPUCuN|QxOzhizszN NY\CSGVbW0GQR1XS
HSC-2 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP6T3JKSzVyPUCuN|QxPTNizszN Mn3mV2FPT0WU
A3-KAW NFnRcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13OXWlEPTB;MD6zOFE3OiEQvF2= MknBV2FPT0WU
COLO-684 NGfMXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjI[5Y3UUN3ME2wMlM1PTBzIN88US=> NGr1UW9USU6JRWK=
NCI-H2405 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwM{S2N|Eh|ryP MlPGV2FPT0WU
NCI-H2228 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\sRZM4UUN3ME2wMlM2OzV5IN88US=> MmW5V2FPT0WU
NB13 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHYTWM2OD1yLkO2PFI6KM7:TR?= MkDHV2FPT0WU
no-11 M{K4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjUWGFKSzVyPUCuN|Y6PSEQvF2= NUDwbVRrW0GQR1XS
DK-MG Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDoPW1KSzVyPUCuN|cyQDhizszN M4nBSHNCVkeHUh?=
NBsusSR MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1VWlEPTB;MD6zO|I5PSEQvF2= M3;1ZXNCVkeHUh?=
KP-N-YS M4DoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj6WXppUUN3ME2wMlM4PDZ|IN88US=> M37KSXNCVkeHUh?=
CFPAC-1 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYN5NKSzVyPUCuN|c2OThizszN MX\TRW5ITVJ?
KARPAS-45 NU\1Spp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTve3dCUUN3ME2wMlM4QDZ{IN88US=> MlTuV2FPT0WU
NCI-H1793 NX;NXHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm4XGJKSzVyPUCuN|g2OSEQvF2= NWnQb5RxW0GQR1XS
HCE-T M4nRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7kPXU5UUN3ME2wMlM5PjB|IN88US=> MlrBV2FPT0WU
NCI-H520 NULDSWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\3PZRKSzVyPUCuN|g4ODNizszN NV\pXXUxW0GQR1XS
HCC2157 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rRe2lEPTB;MD6zPFc5OSEQvF2= M3jVSnNCVkeHUh?=
EW-18 NU\MXG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;nXmFKSzVyPUCuN|g6PDFizszN NWn1PZBkW0GQR1XS
RO82-W-1 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlezTWM2OD1yLkO5Olk6KM7:TR?= NX;EVGFuW0GQR1XS
HuP-T3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmy[os6UUN3ME2wMlQxOTR|IN88US=> MknTV2FPT0WU
PANC-10-05 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\XTWM2OD1yLkSxNVch|ryP M2jpXHNCVkeHUh?=
NCI-H1703 NXW3TpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwNEG0OFYh|ryP NXPmZ5FsW0GQR1XS
TE-10 NF\SO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\4TWlEPTB;MD60NVQ1PyEQvF2= NHnmOpBUSU6JRWK=
HOS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W1RmlEPTB;MD60NVY5OiEQvF2= MmjOV2FPT0WU
LN-405 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TzS2lEPTB;MD60NVY5PyEQvF2= M2\tb3NCVkeHUh?=
A427 NUfMN2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3PTWM2OD1yLkSxPVgyKM7:TR?= MWrTRW5ITVJ?
CAL-12T M37VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jIR2lEPTB;MD60Nlc5KM7:TR?= MlXXV2FPT0WU
SW756 NIDOOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHQTWM2OD1yLkS0NVg{KM7:TR?= M{PjUHNCVkeHUh?=
YAPC MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDsdJBIUUN3ME2wMlQ2ODhizszN MoHTV2FPT0WU
GOTO NEe3UItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDN[GlFUUN3ME2wMlQ2OTZizszN NUPZdo5HW0GQR1XS
C3A MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDhPVJKSzVyPUCuOFU1OzdizszN M1faSnNCVkeHUh?=
UM-UC-3 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fHOWlEPTB;MD60OVQ4KM7:TR?= NGPCbWtUSU6JRWK=
NCI-H1573 M1PGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX6VZM{UUN3ME2wMlQ2PTZ7IN88US=> NYXSPIpwW0GQR1XS
LS-411N NEPjN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvQUpFKSzVyPUCuOFY2OjdizszN MlL4V2FPT0WU
COR-L23 NVnQ[ZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLHTnFKSzVyPUCuOFY4PjRizszN M4m5RnNCVkeHUh?=
HCE-4 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknCTWM2OD1yLkS3OFQ3KM7:TR?= M3jNdnNCVkeHUh?=
NCI-H2291 NWDWV2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rwVGlEPTB;MD60O|g6PiEQvF2= MYrTRW5ITVJ?
A101D NH7jd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwNEiwOVMh|ryP M33SVnNCVkeHUh?=
HT-3 NGS5b3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[wZWlEPTB;MD60PFIyPyEQvF2= MmKwV2FPT0WU
HOP-62 NEPDTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEm4OlUh|ryP MXHTRW5ITVJ?
PC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jubmlEPTB;MD61NVUxPyEQvF2= MVfTRW5ITVJ?
CTV-1 M4rZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS1TWM2OD1yLkWyOlY6KM7:TR?= NEXwN|ZUSU6JRWK=
PANC-08-13 M37a[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTufpVKSzVyPUCuOVMyPzdizszN MkHMV2FPT0WU
CAL-120 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNUOzPVkh|ryP M{nzNnNCVkeHUh?=
UMC-11 NWOxbVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD1yLkW1NlM1KM7:TR?= M3vjVnNCVkeHUh?=
MSTO-211H M3;HNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrc5hQUUN3ME2wMlU2PzZ{IN88US=> M{DWTHNCVkeHUh?=
NCI-H2126 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNU[4NVUh|ryP NHqySldUSU6JRWK=
SNU-C2B NFfyfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNUe5O|ch|ryP NGrQVmxUSU6JRWK=
DBTRG-05MG MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj1TWM2OD1yLkW4NFU{KM7:TR?= MoGzV2FPT0WU
MKN1 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvRTWM2OD1yLkW4O|g{KM7:TR?= NYLDTFF4W0GQR1XS
ES3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNUmxNlQh|ryP M4DzWHNCVkeHUh?=
OVCAR-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNUmzOFEh|ryP MX7TRW5ITVJ?
ACHN MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnMRYNKSzVyPUCuOlA2PjlizszN MUDTRW5ITVJ?
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD1yLk[wO|Y{KM7:TR?= NFnCb4RUSU6JRWK=
CP66-MEL NGrzZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH31ZXFKSzVyPUCuOlA6PjlizszN NYPYXGZYW0GQR1XS
NCI-H661 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNkGxNFQh|ryP NU\KZpNZW0GQR1XS
UACC-893 NIDOTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OzbmlEPTB;MD62N|Y5OSEQvF2= MUDTRW5ITVJ?
JVM-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHjVohTUUN3ME2wMlY{QDB2IN88US=> NYPWZpJLW0GQR1XS
SF268 M3Xw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nwPWlEPTB;MD62OFM1QSEQvF2= MYLTRW5ITVJ?
OCI-AML2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDJUpNKSzVyPUCuOlU{QTdizszN NYHGU2x1W0GQR1XS
RPMI-8226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T5VGlEPTB;MD62OlMzOyEQvF2= M4DhcnNCVkeHUh?=
MKN28 NHLKWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzFOm9KSzVyPUCuOlY3OjRizszN M4ixeHNCVkeHUh?=
MDA-MB-453 NYTzemE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjufGZKSzVyPUCuOlcyQCEQvF2= NU\LTppDW0GQR1XS
BV-173 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNki2O|kh|ryP NFOzd45USU6JRWK=
NCI-H358 M125[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnOTWM2OD1yLk[4O|I3KM7:TR?= MmXEV2FPT0WU
NCI-H1651 NGXGeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7OTWM2OD1yLkeg{txO MXrTRW5ITVJ?
MDA-MB-415 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDzbZBKSzVyPUCuO|A5OjlizszN MWjTRW5ITVJ?
8305C NHH2XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD1yLkeyOFk5KM7:TR?= NHrTbVNUSU6JRWK=
EFM-19 NVrOOFViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPD[IdKSzVyPUCuO|M3PzFizszN NUKxW45pW0GQR1XS
RERF-LC-MS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dm[mlEPTB;MD63OFYyOyEQvF2= MV7TRW5ITVJ?
A388 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXYcZJKSzVyPUCuO|Y1PjdizszN NH\KcYZUSU6JRWK=
GI-ME-N MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwN{eyN|Uh|ryP Ml[5V2FPT0WU
IGR-1 NXG2dYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwN{mwOFMh|ryP NXjLOIlpW0GQR1XS
LNCaP-Clone-FGC Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLISFVsUUN3ME2wMlgxODB2IN88US=> MXnTRW5ITVJ?
SK-MEL-3 NInC[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvnfINKSzVyPUCuPFE2ODhizszN M{P3T3NCVkeHUh?=
UACC-257 NX6yemxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHhTWM2OD1yLkiyNlMyKM7:TR?= M1XUXnNCVkeHUh?=
OE33 NYe1d|dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nqXmlEPTB;MD64OVExOSEQvF2= M1j6S3NCVkeHUh?=
QIMR-WIL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HIXWlEPTB;MD64OVE1OSEQvF2= NHHaZlFUSU6JRWK=
NCI-H2009 NVO1eWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwOEWzNVEh|ryP Mnn4V2FPT0WU
NCI-H522 NWjQ[5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLJeHhKUUN3ME2wMlg4Pzh|IN88US=> NETy[5NUSU6JRWK=
Saos-2 NUXSdG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOEe4O|Eh|ryP NFq4e45USU6JRWK=
NB17 NIXX[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwOEiwNlUh|ryP NVOzcWVSW0GQR1XS
D-392MG NEj2UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT3[2ExUUN3ME2wMlg6OzV4IN88US=> NVf2TGxPW0GQR1XS
SHP-77 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjaVIZKSzVyPUCuPVA1QDVizszN MmXuV2FPT0WU
SK-MEL-30 NHnwU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwOUGxPFUh|ryP M2DK[nNCVkeHUh?=
GCIY NFexXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[2fVB1UUN3ME2wMlkyQDR|IN88US=> M3;r[3NCVkeHUh?=
HCC70 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTnN4pqUUN3ME2wMlkzODV7IN88US=> MUHTRW5ITVJ?
LU-65 NH\BVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2SIFKSzVyPUCuPVI2QTFizszN NV:zVYRWW0GQR1XS
NCI-H1563 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1yLkm0PFY2KM7:TR?= M3vQfXNCVkeHUh?=
KURAMOCHI NInMV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe4fGdKSzVyPUCuPVUyQTJizszN NGLSZWlUSU6JRWK=
PA-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwOUW0NlQh|ryP NFHnOI9USU6JRWK=
NOS-1 M1nDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwOUe0PFkh|ryP NY\TXJZYW0GQR1XS
NCI-H69 M{HHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwOUe2N|Qh|ryP NHn2PFNUSU6JRWK=
KYSE-450 M2HyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BTWM2OD1yLkm4OlI3KM7:TR?= MmW0V2FPT0WU
8505C NV7rVpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC3eoVKSzVyPUCuPVk6QDJizszN MlrEV2FPT0WU
TGBC24TKB NUj3OJNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwMECwPFQh|ryP MUDTRW5ITVJ?
PFSK-1 NELXWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvsNGN5UUN3ME2xMlAyPDJ6IN88US=> MljGV2FPT0WU
EKVX MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImyTZJKSzVyPUGuNFMyOjFizszN M{TpVXNCVkeHUh?=
RCM-1 NIPJTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PJVmlEPTB;MT6wOVUxPyEQvF2= NUf3epp7W0GQR1XS
SW900 NUDOTJVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGfVlKSzVyPUGuNFc5OyEQvF2= NV;3UFZmW0GQR1XS
D-542MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILjc3RKSzVyPUGuNFc5PTVizszN MUnTRW5ITVJ?
SK-PN-DW MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Ob2lEPTB;MT6xNFA2PiEQvF2= M4fzNHNCVkeHUh?=
NCI-H727 NHfQVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojoTWM2OD1zLkGwNVU1KM7:TR?= NEPkWpFUSU6JRWK=
SW837 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK0R|RKSzVyPUGuNVA6PTRizszN NH\zN|ZUSU6JRWK=
BT-20 NVjkN4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LUVmlEPTB;MT6xNVIxPCEQvF2= MnPFV2FPT0WU
RH-18 M2n1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwMUOxNFMh|ryP NUXFbIh1W0GQR1XS
TE-12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPyTWM2OD1zLkGzN|M{KM7:TR?= NHf4[XhUSU6JRWK=
NB10 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMUOzOFQh|ryP MVzTRW5ITVJ?
AU565 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0fnRKSzVyPUGuNVU6PzNizszN NVXxO2w1W0GQR1XS
OAW-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nMemlEPTB;MT6xPFMxPiEQvF2= M3;nO3NCVkeHUh?=
DJM-1 M4LhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnDXpVJUUN3ME2xMlE6QDhzIN88US=> MWjTRW5ITVJ?
HH NIjZWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnud4lKSzVyPUGuNlM5OzFizszN MXPTRW5ITVJ?
LAMA-84 NHKzOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvGTWM2OD1zLkK3N|k1KM7:TR?= NX;NVHBUW0GQR1XS
KNS-42 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXIZlNuUUN3ME2xMlMxOjl4IN88US=> MnS4V2FPT0WU
NCI-H2052 NES0S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXyU2ZKSzVyPUGuN|A2ODdizszN MWTTRW5ITVJ?
MLMA NGfvZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG0NZFqUUN3ME2xMlMzPDB5IN88US=> MU\TRW5ITVJ?
NB12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3[YRpUUN3ME2xMlM2PjN4IN88US=> MYHTRW5ITVJ?
NCI-H1838 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwM{[zNFYh|ryP M1OxVHNCVkeHUh?=
NCI-H526 MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjtc5pKSzVyPUGuN|c5PTNizszN M1\VSXNCVkeHUh?=
LS-123 NGDZNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwM{mwPVQh|ryP NYLafW9{W0GQR1XS
HDLM-2 NUK2ZnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XY[WlEPTB;MT6zPVI4OSEQvF2= M1\1cnNCVkeHUh?=
MC-IXC M2SwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwNEKzO|Eh|ryP M3HmeHNCVkeHUh?=
HCT-15 NIrMT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzWUpVKSzVyPUGuOFMxPjhizszN MV\TRW5ITVJ?
NCI-H596 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPiTWM2OD1zLkS1NFYyKM7:TR?= Mnn5V2FPT0WU
ZR-75-30 M4D0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XhfmlEPTB;MT60O|A5OiEQvF2= NIn4ZoVUSU6JRWK=
A704 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXsdFVkUUN3ME2xMlY3PTZ|IN88US=> NF7G[3lUSU6JRWK=
OVCAR-4 NHfVNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfvXHdIUUN3ME2xMlY6PjB5IN88US=> MmC4V2FPT0WU
SW1417 NXS2T5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX5TWM2OD1zLkeyPFQ6KM7:TR?= M1H3UHNCVkeHUh?=
CAS-1 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG0bpVZUUN3ME2xMlc{QTN4IN88US=> M3fzdHNCVkeHUh?=
IST-SL1 M1TZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwN{m3OVkh|ryP NILRVHdUSU6JRWK=
A253 M2H5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nrc2lEPTB;MT64NlI{QSEQvF2= M2PqS3NCVkeHUh?=
EW-16 NXLBd3hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XyTWlEPTB;MT64Nlg4PSEQvF2= NFTCNJNUSU6JRWK=
SK-NEP-1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwOE[5PFgh|ryP NES3OVhUSU6JRWK=
NCI-H226 M4e0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:4TWM2OD1zLki5N|U6KM7:TR?= M2rtOXNCVkeHUh?=
HOP-92 M{\iUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwOU[wPVkh|ryP MmPaV2FPT0WU
NCI-H441 M4PPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMEKzN|ch|ryP NUn3PHNkW0GQR1XS
LU-139 M4H3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe5Z2p[UUN3ME2yMlA{OTF2IN88US=> NHX1N|hUSU6JRWK=
SJRH30 M1nIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXTb3JRUUN3ME2yMlA1OjV|IN88US=> MVrTRW5ITVJ?
MG-63 M{Pp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoroTWM2OD1{LkG0NVEyKM7:TR?= NXvjcZN2W0GQR1XS
NH-12 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\3R3hKSzVyPUKuNVUxODZizszN MlvVV2FPT0WU
NB7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjjTWM2OD1{LkG5Olc{KM7:TR?= M3XFNXNCVkeHUh?=
LB771-HNC M1XjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtVGxKSzVyPUKuNlA2QTVizszN NH74W2pUSU6JRWK=
HCC1569 NGTWNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nDSWlEPTB;Mj6yOFU5OyEQvF2= NXHHS4Z1W0GQR1XS
D-283MED M{L4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JTmlEPTB;Mj6yOFc5OiEQvF2= MlTpV2FPT0WU
J-RT3-T3-5 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjnOGNKSzVyPUKuNlU{PTFizszN MoHnV2FPT0WU
ATN-1 NVmyOmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rZNmlEPTB;Mj6zN|A5OiEQvF2= NEjkUHNUSU6JRWK=
HCC1954 NIP2c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HCb2lEPTB;Mj6zOFQxQCEQvF2= NYj3R2lJW0GQR1XS
SCC-15 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvLRohKSzVyPUKuN|k{OTJizszN NH7EdWdUSU6JRWK=
COLO-668 NHrGOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojRTWM2OD1{LkSzNkDPxE1? NFyzbVVUSU6JRWK=
LB373-MEL-D NFrlOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz0TWM2OD1{LkW0Olc4KM7:TR?= MlPRV2FPT0WU
no-10 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxUoFKSzVyPUKuOVQ6PDdizszN NGLXUZhUSU6JRWK=
HT-1197 M2\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj5TWM2OD1{Lk[zNVg5KM7:TR?= M{j6O3NCVkeHUh?=
DU-145 NYnMSHBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnLTWM2OD1{Lke5NVYzKM7:TR?= NV32TYpVW0GQR1XS
SK-N-AS NHL0UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnHTWM2OD1{Lki0OlkzKM7:TR?= NILKOWNUSU6JRWK=
MOLT-4 M3;JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorFTWM2OD1{Lki1N|IzKM7:TR?= MW\TRW5ITVJ?
EW-22 NHu0SXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCxTWM2OD1{LkmyPFQyKM7:TR?= NH\sXpZUSU6JRWK=
DB NX;GV2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHOTZlKSzVyPUKuPVc4PTlizszN M17PZ3NCVkeHUh?=
HL-60 NYfBbVlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwMESzO|Yh|ryP NFTKV2dUSU6JRWK=
SK-N-DZ M{TuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LnNGlEPTB;Mz6wOVA4PSEQvF2= NIfHbWtUSU6JRWK=
NY M4\sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFexWIhKSzVyPUOuNFg2PDJizszN MmfOV2FPT0WU
T47D M3zGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXhd3dKSzVyPUOuNVA2PThizszN MYDTRW5ITVJ?
NCI-H2029 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW0R|lGUUN3ME2zMlIzPDd5IN88US=> NYL3S456W0GQR1XS
KARPAS-299 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHnTWM2OD1|LkK2NFI4KM7:TR?= MXXTRW5ITVJ?
KM-H2 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPTT2NKSzVyPUOuN|A3QCEQvF2= M4nPPHNCVkeHUh?=
CHP-134 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrDZo5KSzVyPUOuOFc{QSEQvF2= MYPTRW5ITVJ?
22RV1 NEXrbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi3OGZkUUN3ME2zMlQ6OTZ6IN88US=> MoLLV2FPT0WU
NB5 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwNUC2PFkh|ryP M{exfXNCVkeHUh?=
CW-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nZNGlEPTB;Mz61OVMyPCEQvF2= M1TKTXNCVkeHUh?=
EFO-21 M1POOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXpOXZtUUN3ME2zMlU3QTRizszN M{f0cHNCVkeHUh?=
HuH-7 M17TWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET0RVhKSzVyPUOuOVg1OTRizszN Mn;qV2FPT0WU
ALL-PO M1v5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H4bGlEPTB;Mz62NlM{PSEQvF2= Ml;FV2FPT0WU
EM-2 M3OyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnRSYFKSzVyPUOuOlkxOTFizszN MVHTRW5ITVJ?
KLE NULWZnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X2N2lEPTB;Mz63N|AzQSEQvF2= Mn;RV2FPT0WU
NEC8 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLTWM2OD1|LkmxPFA5KM7:TR?= MkTpV2FPT0WU
KP-N-YN MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jUZ2lEPTB;Mz65N|Q4PiEQvF2= MmqxV2FPT0WU
SK-MEL-1 NIDndYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrLTWM2OD12LkCzOVE5KM7:TR?= NUTGRnpoW0GQR1XS
CAL-54 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnhRW5KSzVyPUSuNFU6OSEQvF2= MlHKV2FPT0WU
MS-1 M1fBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwMU[xOVUh|ryP MmLEV2FPT0WU
NCI-H209 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwMkm5PVkh|ryP M333WXNCVkeHUh?=
NOMO-1 NF\Ud|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwM{KxN|Eh|ryP MmHEV2FPT0WU
RPMI-2650 M2jidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDBTWM2OD12LkO2N|I4KM7:TR?= NVzF[GxJW0GQR1XS
NCI-H810 NYfofYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsUmlEPTB;ND6zPVc{PiEQvF2= MXHTRW5ITVJ?
Ca9-22 M2rqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD12LkS1OlkyKM7:TR?= NYDiToJ{W0GQR1XS
ES4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvJcHVLUUN3ME20MlQ4ODl3IN88US=> NXnHR3NWW0GQR1XS
ES6 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjTTWM2OD12LkS5OlU4KM7:TR?= MmXOV2FPT0WU
DMS-114 NE\3b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvLTWM2OD12LkW0OlkyKM7:TR?= MXTTRW5ITVJ?
ONS-76 NF3wUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MO2VVUUN3ME20MlU4QTVizszN M3rC[nNCVkeHUh?=
K-562 M1LVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnjXHR{UUN3ME20Mlc{QDF2IN88US=> NYLObpppW0GQR1XS
MHH-NB-11 NHHne|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jsSGlEPTB;ND63OVQ3OSEQvF2= MULTRW5ITVJ?
Calu-3 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInPR49KSzVyPUSuO|g2PDhizszN M4WyVXNCVkeHUh?=
HT55 NWnnbWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjtW2VEUUN3ME20Mlg1PTR3IN88US=> M3S3OnNCVkeHUh?=
SK-N-FI NVy4[29TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPRVdKSzVyPUSuPFUxODlizszN MX7TRW5ITVJ?
ES1 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwOE[wOVch|ryP M3jhRnNCVkeHUh?=
SF126 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnVUJJ5UUN3ME20Mlk{OTh2IN88US=> MWTTRW5ITVJ?
ES5 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwMUK0Nlch|ryP MXfTRW5ITVJ?
LoVo M3eycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2zTWM2OD13LkG1PFcyKM7:TR?= NHrjTWFUSU6JRWK=
SNU-387 NUe2SolTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H2W2lEPTB;NT6zNlM{QSEQvF2= NGLQPWRUSU6JRWK=
C8166 NULud2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETjeIxKSzVyPUWuN|Y{OzlizszN NICxU3JUSU6JRWK=
LS-1034 M3LpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnyO|lKSzVyPUWuOFI{ODdizszN M1HZTHNCVkeHUh?=
GR-ST MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD13LkWyNlAyKM7:TR?= NX\M[|ByW0GQR1XS
NCI-H1092 NETpUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PkfmlEPTB;NT63Nlg1OyEQvF2= NY\obHlmW0GQR1XS
647-V NHTCe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:wTWM2OD13Lke0O|A3KM7:TR?= NXe5PIlYW0GQR1XS
EW-13 NXyxToQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrvTWM2OD13Lke2OlI4KM7:TR?= NHjuUW1USU6JRWK=
KGN NH2wNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TuU2lEPTB;Nj6wPVkzOSEQvF2= NGHuOpRUSU6JRWK=
D-423MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrmV4lKSzVyPU[uOFAzQDRizszN M4fyWHNCVkeHUh?=
ECC10 NXLyOGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\2TGlEPTB;Nz6xNFExOSEQvF2= MVjTRW5ITVJ?
TE-5 NFTIU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXWcIYxUUN3ME23MlQyOjl6IN88US=> MoLyV2FPT0WU
P12-ICHIKAWA NFXsPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\FTWM2OD15LkS1OVI{KM7:TR?= MkDIV2FPT0WU
NCI-H82 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq1W|hKSzVyPUeuOFU4ODFizszN NEDZTGFUSU6JRWK=
NCI-H1993 M33sSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwOEOwOlMh|ryP M4njNHNCVkeHUh?=
RH-1 M4rEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorCTWM2OD15Lki1NlQ1KM7:TR?= MUnTRW5ITVJ?
SW948 NHHSSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zybGlEPTB;Nz65OlA1QSEQvF2= NYCxRoFyW0GQR1XS
CAL-33 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jGWGlEPTB;Nz65PVk{QCEQvF2= NIW1RZBUSU6JRWK=
U-266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO4WZNKSzVyPUiuNVU4PzdizszN NYjpOYRiW0GQR1XS
CAL-72 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7kOY1SUUN3ME24MlIxOzJizszN NFTyflBUSU6JRWK=
SNU-423 NInHOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PHSmlEPTB;OT6zOlY3PiEQvF2= Mm\JV2FPT0WU
KG-1 NVe4UHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTlwNUi0OVYh|ryP MmPiV2FPT0WU
HCC1395 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG5dI1KSzVyPUmuPVI{PTJizszN MnzSV2FPT0WU
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r4bmlEPTB;MUCuPFg6OiEQvF2= M4DUR3NCVkeHUh?=
MKN7 NFHiO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG4[4s2UUN3ME2xNE46PzZ3IN88US=> MWnTRW5ITVJ?
697 M{n3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XibGlEPTB;MUGuNVQ4OiEQvF2= MlPDV2FPT0WU
LU-135 NITwSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnToTWM2OD1zMT6yN|A4KM7:TR?= NUn3RZNpW0GQR1XS
ES7 NXixOld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjrXW4xUUN3ME2xNU4{OzF|IN88US=> MWPTRW5ITVJ?
SK-HEP-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M335e2lEPTB;MUGuO|Y1PiEQvF2= NFm0PXNUSU6JRWK=
BEN NUfZdGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLki1NUDPxE1? MVfTRW5ITVJ?
NCI-H1770 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlTWM2OD1zMj6xNlYh|ryP NWqzNnFFW0GQR1XS
SW13 M3joOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P5[2lEPTB;MUKuNVU1OSEQvF2= MXvTRW5ITVJ?
MZ1-PC NWi1WmptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrMZ4hmUUN3ME2xNk42PDV{IN88US=> MUfTRW5ITVJ?
Mo-T MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTNclVEUUN3ME2xNk44PDJzIN88US=> MVTTRW5ITVJ?
HLE NEHuW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsSGlEPTB;MUKuPFIyPSEQvF2= NXHIPXNpW0GQR1XS
RCC10RGB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF|Lk[3NUDPxE1? M4LjdHNCVkeHUh?=
COLO-320-HSR NVnVe5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPD[5dKSzVyPUGzMlc{QDFizszN M3PQc3NCVkeHUh?=
BHT-101 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2T2lEPTB;MUOuPFM1PSEQvF2= MoLJV2FPT0WU
OCUB-M M{S5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTtdYNKSzVyPUG0MlE3ODJizszN NUn3b3ZlW0GQR1XS
MEG-01 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2LkO3NFgh|ryP NEDiUWtUSU6JRWK=
RS4-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGxe2lKSzVyPUG0Mlc1OiEQvF2= Mn7UV2FPT0WU
MN-60 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\TSGhZUUN3ME2xOE44QDl2IN88US=> MWnTRW5ITVJ?
NCI-H1304 M2XCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF3LkC0NlUh|ryP MXfTRW5ITVJ?
Ramos-2G6-4C10 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF3LkC1PFEh|ryP M2r1VXNCVkeHUh?=
NCI-H2342 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXOXHVCUUN3ME2xOU4zODR2IN88US=> NUfwWJhDW0GQR1XS
LAN-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne5TWM2OD1zNT60OFE1KM7:TR?= NHH2TWJUSU6JRWK=
JVM-2 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF3LkW3OFgh|ryP MWnTRW5ITVJ?
P30-OHK NF7MTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PVO2lEPTB;MU[uNFYyPCEQvF2= MWXTRW5ITVJ?
C-33-A MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITMd|RKSzVyPUG2MlYzOTRizszN MoLuV2FPT0WU
RPMI-8866 NVP4OXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHnfIlKSzVyPUG2Mlg1QTZizszN MnPXV2FPT0WU
NCI-H630 M2TiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF4Lki1N|ch|ryP NIX6VZNUSU6JRWK=
KYSE-140 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF5LkKwNlgh|ryP NGTVWpFUSU6JRWK=
T84 NEjPfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF6Lki2PVUh|ryP Mn20V2FPT0WU
KU-19-19 NYLnbm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PybGlEPTB;MUiuPVYxQCEQvF2= NFzkXJNUSU6JRWK=
BALL-1 NFLDb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Nd4RKSzVyPUG5MlM{QTlizszN NFezOXRUSU6JRWK=
Calu-6 NVLrW41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfLTWM2OD1zOT60PVIh|ryP M2HXO3NCVkeHUh?=
EGI-1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\IRnhKSzVyPUG5MlU6QCEQvF2= NVq0Ond3W0GQR1XS
MFH-ino MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPnZlBiUUN3ME2xPU44PDV2IN88US=> NHzTZnlUSU6JRWK=
GB-1 M3PUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD1{MD6zOVM2KM7:TR?= MXrTRW5ITVJ?
NCI-H1693 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL1S404UUN3ME2yNE43PTB3IN88US=> NWnvVm1LW0GQR1XS
SW1116 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJyLkmzOlIh|ryP MWHTRW5ITVJ?
H-EMC-SS NEHKWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTtb3pPUUN3ME2yNk4xPDVizszN MYjTRW5ITVJ?
D-502MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjtNpNKSzVyPUKyMlgzPjFizszN MUfTRW5ITVJ?
IA-LM M{G2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKwcmlKSzVyPUKzMlI1QTNizszN NGHndmJUSU6JRWK=
SW1463 NFTjOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ|Lke5JO69VQ>? M1nQTXNCVkeHUh?=
JAR NUCxUVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHwTWM2OD1{ND6zNlk{KM7:TR?= NX3OO|l7W0GQR1XS
HT MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TXfmlEPTB;MkSuOFc2OyEQvF2= NUf1ZYtmW0GQR1XS
LCLC-103H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHBTWM2OD1{ND64OFQ6KM7:TR?= NHPKfoJUSU6JRWK=
SNU-449 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXtSpRKSzVyPUK0Mlg4PDFizszN NXjrV3J2W0GQR1XS
KE-37 M2HvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ3LkC5Nlgh|ryP NUj0bHF{W0GQR1XS
NCI-H1623 NVftclV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[4TWM2OD1{Nz6xN|A{KM7:TR?= MVTTRW5ITVJ?
MOLT-13 Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjrPI03UUN3ME2yO{4{PTF4IN88US=> NXfKenlJW0GQR1XS
COLO-741 M{LwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCc2lEPTB;M{GuN|M{OyEQvF2= M4nGUXNCVkeHUh?=
NB6 NWW3dolHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImwe|lKSzVyPUOyMlI5PzZizszN M3K4[3NCVkeHUh?=
MOLT-16 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi1N5FlUUN3ME2zN{4xODV3IN88US=> MlvhV2FPT0WU
IST-MES1 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTXTWM2OD1|ND6wOVQyKM7:TR?= M17z[nNCVkeHUh?=
A4-Fuk NESzeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HVbWlEPTB;M{WuNFY3KM7:TR?= MnLDV2FPT0WU
CAL-85-1 M3rzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe3cWRPUUN3ME2zOU4zQDF5IN88US=> M4Py[HNCVkeHUh?=
CCRF-CEM Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\TTWM2OD1|Nz6xOVM3KM7:TR?= MXTTRW5ITVJ?
HAL-01 NI\CcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjudIVXUUN3ME2zPE41QDh7IN88US=> M1nUc3NCVkeHUh?=
HEL M3nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorzTWM2OD12Mz6zOFA6KM7:TR?= M4fmd3NCVkeHUh?=
EW-1 NXHTcWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;L[2VIUUN3ME20N{41PzZ6IN88US=> NWfhcIFTW0GQR1XS
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi1ZW9KSzVyPUS1MlEyQTlizszN MorzV2FPT0WU
ABC-1 M3q4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfmOoRKSzVyPUS2Mlg2OzhizszN M4[1WXNCVkeHUh?=
NCI-H446 NWnCPIptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX74OnI{UUN3ME20PE42ODV6IN88US=> NH;ROZlUSU6JRWK=
MHH-PREB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Gy[GlEPTB;NEmuOlAxPyEQvF2= MWDTRW5ITVJ?
DOHH-2 M4HxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHuUZZrUUN3ME20PU43PjV4IN88US=> MV\TRW5ITVJ?
GCT NGfQfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmblc5UUN3ME20PU43QTd4IN88US=> NIP6cohUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID